On Thursday, 3006 stocks advanced, 990 declined and 107 3006remained unchanged, with an advance decline ratio of 3.04 on the ...

The pharma giant has received the CDSCO nod to import sodium zirconium cyclosilicate powder for oral suspension (Lokelma) in ...

AstraZeneca Pharma India Ltd has received approval from India's drug regulator to import and sell sodium zirconium ...

AstraZeneca Pharma India has received approval to import and sell sodium zirconium cyclosilicate (Lokelma) for treating hyperkalemia in adults in India. The drug is indicated for the treatment of ...

Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, February 27th. Zacks Research analyst R.

New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

Farxiga sales were up 21% (22% at CER) to $1.94 billion, and Lokelma sales increased 35% to $150 million. Respiratory & Immunology (R&I) sales increased 27% (28% CER) to $2.13 billion. Breztri ...

AstraZeneca’s hyperkalaemia treatment Lokelma has been approved in Europe, a relief to the company after two years of delay to the potential blockbuster. Formerly known as ZS-9, Lokelma (sodium ...